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Anti-HBs titersUniversal vaccination is the most effective strategy to control hepatitis B virus (HBV) infection. In
Argentina, vaccination against HBV was incorporated in year 2000 for newborns and in 2003 for 11 years
old children. However, there is a paucity of data about protection levels against HBV infection.
The aim of this work was to determine the prevalence of seroprotective anti-HBs antibodies (aHBs) in
Argentina.
Serum samples negative for HBsAg and anti-HBc from 132 children born after year 2000 and 762 blood
donors, older than 18 years, from five centers across the country, were analyzed for aHBs.
Titers 10 mIU/mL were observed in 74/132 children (56.1%) and 336/762 (44.1%) in blood donors. The
median age for blood donors was 33.9 (23–43); from them, 210 (27.6%) were born after 1992 and, there-
fore, were catch-up by vaccine implementation at 11 years old age. Donors born in 1992 or before
showed a significantly lower frequency of protection (32.2%) compared to donors born after 1992
(75.2%), p < 0.0001. In addition, significant differences were observed in the status of seroprotection
between different participating centers (p = 0.024).
Implementation of HBV vaccine in 2000 and 2003 implied an overall increase of the aHBs seroprotec-
tive rates, with a particularly adequate response in children vaccinated at 11 years old age. The observed
results suggest that population born in 1992 or before is currently the most susceptible. Consequently, it
would be advisable to become aware of the risk of transmission in this age group and to stress this pop-
ulation vaccination campaigns.
 2020 Elsevier Ltd. All rights reserved.1. Introduction
Hepatitis B virus (HBV) infection and HBV-related complica-
tions remain as a major global public health problem [1]. Approx-
imately 260 million people are chronically infected and almost 1
million deaths occur yearly, most of them from complications
including cirrhosis and hepatocellular carcinoma [2].
In Argentina, the estimated prevalence of HBV infection in
blood donors is 1–2% with an uneven distribution in different
F.A. Di Lello et al. / Vaccine 38 (2020) 2678–2682 2679regions around the country [3]; the infection rate in patients aged
15–24 years old is 1.14 per 100,000 [4]. In addition, prenuptial
studies carried out in four Argentine urban conglomerates during
2013 and 2014 showed an HBsAg prevalence of 0.26% [5].
Although Argentina is considered a low prevalence country,
chronic HBV infection has been the leading cause of fulminant hep-
atitis and the third cause of liver transplantation in the 2005–2011
period [6,7]. Moreover, a latest study reported an unexpected high
frequency of recent infections in the blood donor population [8].
Thus, despite treatment and prevention great progresses, HBV
infection is still a main health problem both globally and
regionally.
HBV vaccine was introduced in the early 80s and the global cov-
erage with the complete scheme of doses is currently estimated to
be higher than 80% [2,9]. In Argentina, vaccination was sequen-
tially implemented: initially, in 1992, for health working personnel
and recommended for groups with risk behaviors (National Law
No. 24.151); then, in 2000, in the National Vaccination Calendar
for newborns (Res. 940/00); and later, in 2003, for 11-year-old chil-
dren (Res. 175/03). Although through these interventions HBV
infection rates decreased among children, the incidence of viral
infection did not declined significantly in the adolescent and adult
population [10]. For this reason, in 2012, the hepatitis B vaccine
was incorporated for adults in Argentina. Consequently, children
born after 2000 have been covered by the newborn mandatory vac-
cination and those born between 1992 and 2000 received the vac-
cine when they reached the age of 11 years old. According to World
Health Organization (WHO) estimates, the Argentine vaccine cov-
erage should be higher than 80% for people born after 1992 [2].
Regardless of these estimates, there is a paucity of accurate data
concerning the protection state for HBV in the Argentine popula-
tion. Moreover, according to data from the Argentine Ministry of
Health, incidence of HBV in children has decreased in the last dec-
ade probably due to universal immunization campaigns. However,
most cases of HBV infection come from people older than 35 years
old [11], age group that is in coincidence with persons not reached
at the beginning of the mandatory vaccine period. Additionally, the
Argentine average age of acute HBV infections is 44 years old, also
in coincidence with the age group not reached by the vaccine
incorporation to the calendar [12]. Therefore, at present, people
born before year 1992 seems to be the main vulnerable population
to HBV infection in the country. However, there is no data regard-
ing immunoprotection for HBV in individuals born after year 1992,
and none local study has addressed this issue until now.
For this reason, the aim of this work was to determine and com-
pare the level of immune protection against HBV in population
from different regions from Argentina, born before and after the
incorporation of universal HBV vaccination.2. Materials and methods
2.1. Study population
Serum samples negative for anti-HBc and HBsAg from 894 indi-
viduals were included in this study. On the one hand, 132 samples
from under 18 children reached by the 2000 vaccine implementa-
tion, who attended a Hospital in Buenos Aires, were retrospectively
collected from June 2013 until December 2018. On the other hand,
762 samples from individuals who attended five blood donor cen-
ters located in the North, South, Central, East and West regions
from Argentina were prospectively collected from February 2019
until May 2019.
This sample group included 210 individuals born after 1992 and
reached by the 11-year-old children vaccine implementation in
2003, and 552 individuals born in 1992 or before, not reached bythe vaccine implementation. Blood donors who were health work-
ers were excluded from the study sample. All participants signed
an informed consent.2.2. Laboratory determinations
Sera were separated and frozen at 20 C until testing. HBV
serological markers aHBc, aHBs and HBsAg were analyzed with
Architect Abbott system; Abbott Diagnostics, Wiesbaden, Ger-
many. All tests were carried out following the manufacturer’s
instructions.2.3. Statistical analysis
Frequencies were compared using the chi-square test or the
Fisher’s test. The Student’s t-test and the Mann-Whitney U were
used for comparing continuous variables. In order to identify pre-
dictors of seroprotective status in the analyzed population, a logis-
tic regression analysis adjusted for age and sex was performed.
Factors associated to seroprotective status in the bivariate analysis
with a p value  0.2 were entered as covariates. The statistical
analysis was carried out using the SPSS statistical software package
release 19.0 (IBM SPSS Inc., Chicago, IL, USA).3. Results
3.1. Population characteristics
One hundred thirty-two children born after 2000 and negative
for anti-HBc and HBsAg were included in the study, 69 (52.3%)
were female and the median age (Q1–Q3) was 10 (5–15) years.
Moreover, samples from 762 blood donors negative for anti-HBc
and HBsAg were analyzed. Their median (Q1–Q3) age was 34 (27–
43) years old and 305 (40.0%) were female. Women were one year
older than men were [34 (27–43) vs. 33 (27–43), respectively
p = 0.016]. Table 1 summarizes the study population characteris-
tics by age group.3.2. aHBs status
From 132 children, 74 (56.1%) have aHBs titers 10 mIU/mL.
There were no significant differences in the rate of seroprotection
by gender [37 (53.6%) for female and 37 (58.7%) for male,
p = 0.555]. Interestingly, aHBs coverage rate in 1 to 5 years old chil-
dren (87.5%) was significantly higher compared to those between 6
and 17 years old (46.0%) (p < 0.001).
As regards blood donors, 336 (44.1%) showed seroprotective
titers. Rates were significantly higher in women than in men
(50.8% vs. 39.6%, respectively p = 0.003).3.3. Association between year of birth and aHBs status in blood donors
There was a significant bias in aHBs protective prevalence
according to whether blood donors were reached or not by the
implementation of the vaccine in the national schedule. In individ-
uals born after 1992 (reached by the 2003 vaccination program),
aHBs seroprotection rates were significantly higher than in individ-
uals born in1992 or before (75.2% vs. 32.2%, respectively
p < 0.0001) (Table 2). When the studied population was separated
by gender, there were no significant differences in seroprotection
frequencies between men and women born after 1992 [86
(72.3%) vs. 72 (79.1%), respectively p = 0.254]. However, significant
differences were found between men and women born in 1992 or
before [95 (28.1%) vs. 83 (38.8%), respectively p = 0.009].
Table 1
Blood donors characteristics by age group (N = 894).
Age group Children (born before 2000) Blood donors (born before 1992) Blood donors (born after 1992) Pa
N 132 552 210
Age Median (IQR) 10 (5–15) 38 (32–46) 24 (21–26) –
By gender
Female 69 (52.3) 214 (38.8) 91 (43.3)
Male 63 (47.7) 338 (61.2) 119 (56.7) 0.250
By region
East (%) na 124 (77.5) 36 (22.5)
Center (%) na 107 (71.8) 42 (28.2)
North (%) na 91 (61.5) 57 (38.5)
West (%) na 109 (72.7) 41 (27.3)
South (%) na 121 (78.1) 34 (21.9) 0.009
na: Not applicable.
a. Comparison of blood donors born before or after 1992.
Table 2
Protective levels of aHBs (10 mIU/ml) by age group (N = 894).
Age group Children (born before 2000) Blood donors (born before 1992) Blood donors (born after 1992) Pa
N 132 552 210
aHBs titer
10 mIU/ml (%)
74 (56.1) 178 (32.2) 158 (75.2) <0.001
By Gender
Female (%) 37 (53.6) 83 (38.8) 72 (79.1) <0.001
Male (%) 37 (58.7) 95 (28.1) 86 (72.3) <0.001
By region
East (%) na 39 (31.5) 23 (63.9) <0.001
Center (%) na 21 (19.6) 33 (78.6) <0.001
North (%) na 30 (33.0) 48 (84.2) <0.001
West (%) na 39 (35.8) 28 (68.3) <0.001
South (%) na 49 (40.5) 26 (76.5) <0.001
na: Not applicable.
a. Comparison of blood donors born before or after 1992.
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mL rates between children and adults born in 1992 or before
(56.1% vs. 32.2%, p < 0.001, respectively) as well as among children
reached by vaccination since year 2000, and adults born after 1992
reached by the vaccine implementation since 2003 (56.1% vs.
75.2%, p < 0.001, respectively).
In a multivariate analysis adjusted by gender, year of birth and
country region, women and people born after 1992 showed higher
seroprotection frequencies [OR 1.68 (1.21–2.32) p = 0.002 and 6.55
(4.53–9.49) p < 0.0001, respectively]. In addition, the East and Cen-
tral regions showed lower seroprotective levels than the South
region. Results of the univariate and multivariate analyses are
shown in Table 3.Table 3
Univariate and multivariate analysis to assess the parameters associated to aHBs  10mIU
Parameter N (%) aHBs  10, n (%)
Gender
Female 305 (40) 155 (50.8)
Male 457 (60) 181 (39.6)
Year of birth
After1992 210 (27.6) 158 (75.2)
1992 or before 552 (72.4) 178 (32.3)
Region
East 160 (21) 62 (38.7)
Central 149 (19.6) 54 (36.2)
North 148 (19.4) 78 (52.7)
West 150 (19.7) 67 (44.6)
South 155 (20.3) 75 (48.4)
AOR: adjusted odds ratio; CI: confidence interval.4. Discussion
WHO has stated different goals that should contribute to elim-
inate hepatitis B as a public health threat. The main objective
includes the universal vaccination, which is the most effective
strategy to achieve a decrease in HBV transmission.
Two strategies allow to supervising the effectiveness of vaccina-
tion plans: on the one hand, the estimation of vaccination coverage
rate and, on the other hand, the advisable evaluation of population
aHBs prevalence. This approach would permit to identify vaccina-
tion campaigns achievements and limitations as well as to recog-
nize the drawbacks in order to focus the resources destination
according to needs./mL in the donor population (N = 762).
p uni-variate AOR (95% CI) p multi-variate
0.003 1.68 (1.21–2.32) 0.002
1
<0.001 6.55 (4.53–9.49) <0.001
1
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tection rates against HBV infection, through aHBs titers, in a repre-
sentative size cohort from Argentina. Overall the seroprotection
levels were lower than the expected ones [2], being suitable for
the population born between years 1992 and 2000, intermediate
for the population reached by universal newborn vaccination since
year 2000, and scarce for people born before 1992. Routine child-
hood immunization against hepatitis B, according to WHO, has
increased globally with an estimated complete scheme coverage
of 84% in 2017 [2]. Individuals reached by the implementation of
the vaccine, either at birth (born after 2000) or catch-up at 11 years
old (born after 1992), showed an increase in the rate of protective
titers, in line with the coverage rate of the vaccine against HBV
estimated by the Argentine Ministry of Health and WHO [2,9].
The lower frequency of protective titers of aHBs in children vac-
cinated at birth compared to those vaccinated at the 11 years old
age may be a consequence, as previously described, to a rapid
decrease of antibody levels observed in the former group [13–
17]. In fact, children between 1 and 5 years old, more recently vac-
cinated, have shown significant higher coverage rates than those
aged 6–17 years old. Likewise, children born after the year 2000,
vaccinated at birth, have shown a higher frequency (24.2%) of
low antibody levels (1–9.99 mIU/mL), compared to those vacci-
nated at the age of 11 years old (9.8%).
Other reasons, in addition to age at the time of vaccination,
whereby children vaccinated at born showed titers between 1
and 9.99 mIU/mL could be an incomplete vaccination schedule or
the application of a pentavalent vaccine formulation, which may
induce low and uneven aHBs titers [18].
The decrease in anti-HBs antibodies over time below the sero-
protection threshold is a controversial issue. Several studies have
shown that individuals with aHBs levels between 1 and 9.99
mIU/mL quickly recover seroprotective aHBs levels after receiving
a booster [19–22], due to immune memory [23,24]. In this context,
the available bibliography widely reports that individuals with
aHBs levels between 1 and 9.99 mIU/mL mostly generate an ade-
quate anamnestic response and, therefore, are considered pro-
tected against HBV infection [25–27]. Consequently, the WHO
does not recommend booster vaccination in successfully immu-
nized individuals [2,28].
Although the donor cohort born after 1992 showed no differ-
ences in the seroprotection rate due to gender or geographic
region, in donors born in 1992 or before, seroprotection rate was
significantly lower in the central region and in men. Levels of vac-
cine coverage variation among regions, in the cohort born in 1992
or before, may be due to demographic differences as well as to the
strength of campaigns and public awareness. Differences in cover-
age rates according to gender could be the consequence of a
greater awareness of the female population as they have a closer
medical control, especially in fertile age.
The low rates of protective aHBs detected in people born in
1992 or before highlight the limited success for the initiative of
adult vaccination promoted in year 2012 to strengthen the control
and elimination of HBV in Argentina. This pitfall is in line with the
high frequency of HBV recent infections observed in blood donor
population, and the average age of persons diagnosed with acute
HBV infections [8,12].
5. Conclusion
The implementation of the HBV vaccine in the Argentine
national calendar meant a significant increase in the population’s
seroprotection rate, which shows the effectiveness of universal
vaccination, either at birth or in adolescence.
In 2016, World Health Assembly has adopted the Global Health
Sector Strategy on viral hepatitis to eliminate hepatitis by 2030[29]. The low rate of protective aHBs titers of individuals born in
1992 or before observed in this study, highlight the necessity to
emphasize health measures pointed to this cohort, in order to
achieve the desired control of HBV transmission. Finally, these
study findings contribute to the national public health system
planning and are useful to control and evaluate the effectiveness
of vaccination plans and campaigns, as well as to guide future
HBV immunization programs in our country.
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